Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving

Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the... Renin-Angiotensin System Blockade Discontinuation and Mortality in Persons With Low Estimated Glomerular Filtration Rate Original Investigation Research Editor's Note Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving Colette DeJong, MD, MS; Richard W. Grant, MD, MPH According to the National Health and Nutrition Examination cohort studies, like the analysis by Qiao et al, can comple- Survey, from 2011 to 2012, an estimated 12% of adults in the ment RCTs by examining the clinical question in more di- US used an angiotensin-converting enzyme inhibitor (ACE-I) verse clinical settings. Compared with the STOP-ACEi trial, 1 2 and 5.8% used an angiotensin receptor blocker (ARB). In this Qiao et al observed nearly 10-fold more patients over a issue of JAMA Internal Medi- longer study period, allowing for greater external validity (al- cine, Qiao et al help inform beit in a predominantly white sample) and a primary end point Related article page 718 the clinical quandary of what of clinical events rather than the surrogate of change in esti- to do when patients taking these drugs show progression of mated glomerular filtration rate. kidney disease. They present results of a retrospective http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving

JAMA Internal Medicine , Volume 180 (5) – May 9, 2020

Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving

Abstract

Renin-Angiotensin System Blockade Discontinuation and Mortality in Persons With Low Estimated Glomerular Filtration Rate Original Investigation Research Editor's Note Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving Colette DeJong, MD, MS; Richard W. Grant, MD, MPH According to the National Health and Nutrition Examination cohort studies, like the analysis by Qiao et...
Loading next page...
 
/lp/american-medical-association/continuation-of-angiotensin-converting-enzyme-inhibitors-and-p9SOcFpLAH

References (3)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2020.0300
Publisher site
See Article on Publisher Site

Abstract

Renin-Angiotensin System Blockade Discontinuation and Mortality in Persons With Low Estimated Glomerular Filtration Rate Original Investigation Research Editor's Note Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving Colette DeJong, MD, MS; Richard W. Grant, MD, MPH According to the National Health and Nutrition Examination cohort studies, like the analysis by Qiao et al, can comple- Survey, from 2011 to 2012, an estimated 12% of adults in the ment RCTs by examining the clinical question in more di- US used an angiotensin-converting enzyme inhibitor (ACE-I) verse clinical settings. Compared with the STOP-ACEi trial, 1 2 and 5.8% used an angiotensin receptor blocker (ARB). In this Qiao et al observed nearly 10-fold more patients over a issue of JAMA Internal Medi- longer study period, allowing for greater external validity (al- cine, Qiao et al help inform beit in a predominantly white sample) and a primary end point Related article page 718 the clinical quandary of what of clinical events rather than the surrogate of change in esti- to do when patients taking these drugs show progression of mated glomerular filtration rate. kidney disease. They present results of a retrospective

Journal

JAMA Internal MedicineAmerican Medical Association

Published: May 9, 2020

There are no references for this article.